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Background: In France, 2–15% of the population is affected annually by influenza, which causes significant
socioeconomic disruption. Nevertheless, despite its importance for policy makers, few published studies have evaluated
the impact of influenza B. Therefore, we assessed the costs associated with influenza B during 2010–2011 in France.
Methods: Cases of lab-confirmed influenza B were analyzed as part of the Influenza B in General Practice Study.
Cost calculations were based on micro-costing methods according to the French Health Insurance (FHI) perspective
(in Euros, 2011). Costs were compared between age groups using the Kruskal–Wallis test, and when significant,
by multiple comparisons based on rank. Moreover, uncertainties were assessed using one-way sensitivity and
probabilistic analyses. Overall economic burden was estimated by multiplying cost per patient, flu attack rate, and
the French population.
Results: A total of 201 patients were included in the study. We found that the mean cost associated with Influenza B
was 72€ (SD: 205) per patient: 70€ (SD: 262) for younger children, 50€ (SD: 195) for older children, 126€ (SD: 180)
for adults, and 42€ (SD: 18) for elderly. Thus, we observed significantly different costs between the distinct age
groups (p<0.0001). Finally, the economic burden of influenza B for the FHI was estimated to be 145 million Euros
(95% CI: 88–201).
Conclusions: Our findings highlight the important impact of influenza B and encourage further investigation on
policy regarding vaccination strategies in France.
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During seasonal influenza epidemics, it is estimated that
5–15% of the world population is affected by acute re-
spiratory infections (ARIs) [1]. According to the World
Health Organization (WHO) these annual epidemics re-
sult in 3–5 million cases of severe illness and 250–500
thousand deaths worldwide [1,2]. In France, during the
2010–2011 influenza season, the incidence of primary
care medical consultations for lab confirmed flu was es-
timated to be 6.7% (6710/100,000; 95% CI: 4411–9009).
This figure represented a typical attack rate in a medium* Correspondence: maria-laura.silva@univ-lyon2.fr
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reproduction in any medium, provided the orintensity flu season when compared with data from re-
cent years, which fluctuated between 2.5% (2007–2008)
and 15% (2012–2013) [3,4].
Influenza viruses circulate during winter months
(November–February in Europe), and epidemics last
8 weeks (on average) [4,5]. Generally, one circulating viral
strain type or subtype is dominant during each season in a
given location. However, in some seasons, there may be
two or three different dominant viruses [6].
Patients with ARI induced by influenza, have the po-
tential to develop a variety of complications, ranging
from minor to life threatening [7]. Nevertheless, the
majority of infected individuals experience only slight
illness, which lasts less than two weeks and requires no
medical intervention. In contrast, others may need medical
consultations and/or work leave, but ultimately develop no
complications [7]. However, influenza can be particularlyd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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chronic diseases. Indeed, these individuals can display an
increased risk of severe complications, including pneu-
monia and fatal illness [8]. Due to the widespread affects
of influenza, the national costs associated with the illness
are of vital importance, especially when considering sick-
ness benefit payments due to work leave and hospital/
emergency care [8].
Policy makers are typically interested in the socioeco-
nomic impact of influenza in order to set priorities for
interventions [9]. However, few studies have evaluated
the costs associated with illness and influenza vaccination
programs [10,11]. Additionally, previous studies were
rarely specific to particular viral strains [12,13]. In fact,
few studies have provided strict investigations of influenza
B or comparisons between influenza B and other viruses
[14]. Furthermore, there have been recent discussions
about whether or not to include two influenza B lineages
within the seasonal influenza vaccine [15,16]. Therefore,
to bridge the gap in knowledge regarding influenza B, a
study entitled “Influenza B in General Practice” (IBGP)
was initiated during the influenza season of 2010–2011.
Notably, the study was designed to cover France and
Turkey in its first phase. The overall aim of the IBGP was
to analyze the morbidity and differential burden of illness
(i.e., influenza-like illness consultations, prescriptions, sick
leave) due to influenza B, including differences in age
groups and lineages.
In this paper, we used data collected from the IBGP
study to assess the impact of influenza illness on the
French economy. Despite the fact that flu B represents
11% (median rate) of the detected influenza cases over
the past eight years, no previous study has assessed the
costs associated with lab-confirmed influenza B in
France [4]. Although some studies regarding influenza B
have been conducted in other countries [17,18], they are
very specific to local practices and health systems, poten-
tially hindering their relevance to the French system.
Indeed, universal healthcare in France is largely financed
by the National Health Insurance [19,20]. Therefore, our
objective was to describe the costs associated with sea-
sonal influenza B during the 2010–2011 season for a
population presenting with ARI, consulting in primary




IBGP was an observational, prospective study conducted
within sentinel surveillance networks in Europe. In France,
the study was approved by the National Ethics Committee
(N°911011) and the National Committee for Protection
of Personal Data (N°11.016). Moreover, the study was
proposed to all practitioners participating in the GROGnetwork (Groupes Régionaux d’Observation de la Grippe),
which included 390 general practitioners (GPs) and 116
pediatricians (2010–2011 season). These physicians were
well distributed throughout the country and were trained
to collect swab specimens and clinical information.
Swabbed patients represented individuals with an ARI,
defined as individuals consulting the practitioner within
seven days (preferably two days) of a sudden onset of
symptoms, including at least one systemic symptom (e.g.,
fever, headache, or myalgia) and one respiratory symp-
tom (e.g., cough, rhinitis, or sore throat). As part of the
routine surveillance for influenza during the whole sea-
son, swabbed patients were ultimately selected based on
ad-hoc sampling, whereas systematic random sampling
was used to select those patients to be swabbed. In this
regard, each practitioner was required to swab the first
ARI patient of each week within his/her specific age
group: 0–4 years (GPs and pediatricians), 5–14 years
(GPs and pediatricians), 15–64 years (GPs) and 65 years
or more (GPs) [21].
The swabs and specimen request forms were then sent
to the collaborating National Influenza Center (NIC,
North and South) [21]. Virological methods were used
for influenza identification and lineage characterization
following the WHO Collaborating Centers recommen-
dations [22]. The laboratories entered the clinical data
and swab identification results into an electronic data-
base. An anonymized version of this database was sent
to GROG coordination [21]. Thus, this routine swab
monitoring technique was used to identify influenza B
cases and recruit patients for follow-up.
Patients recruitment for follow-up
Following confirmation of an influenza B case, the study
coordinator alerted the physician, who then made con-
tact with the patient within 7 ± 2 days after the initial
consultation. The patient was invited to participate in
a follow-up assessment. For adults, oral consent was
acceptable, whereas children required written parental
agreement. For those patients who were not recovered
at first follow-up contact, a further interview was ar-
ranged three weeks later. Thus, three study documents
were used: the initial specimen request form (day 0; D0),
the initial follow-up form (day 7 ± 2; D7), and the final
follow-up form (day 28 ± 5; D28).
The D0 form included patient demographics, presence of
similar cases in the household, vaccination status, presence
of risk factors, and clinical symptoms [21]. The D7 and D28
follow-up forms were identical and were used to collect
information regarding employment, ARI-related medical
consults (e.g., telephone, medical office, or home visits), use
of emergency services, hospitalization, additional tests,
paramedical care, sick leave (work or school), drugs taken,
duration of illness, and continuing symptoms [23].
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The overall use of resources was determined based on
data from three study documents (D0, D7, D28). Illness
duration was defined from the date of illness onset to the
recovery date, and costs were assessed from the French
Health Insurance (FHI) perspective. Cost calculations (in
Euros) were based strictly on a micro-costing approach
[24], which involved analysis of FHI reimbursed fees [25]
and the GROG methodology [23] (Box 1, Additional
file 1). The following items were considered:
 Initial office consultation for ARI (GPs or
pediatricians) [26];
 Follow-up office consultations [26];
 Home visits and additional consultations at the
patient’s domicile [26];
 Telephone consultations (not cost allocated) [26];
 Emergency services (standard non-specific emergency
care pack basis) [27];
 Hospitalizations (hospital care due to influenza
complications) [28,29];
 Vaccine (cost of influenza vaccine, excluding
administration) [30,31];
 Drugs taken (name and number of packs, assessed
in three classes: antibiotics, antivirals, others
[GROG methodology]). The lowest cost for each
drug was used (age adjusted) [23,24,30,31];
 Additional tests costs (out of hospital) [32,33];
 Paramedical care costs (out of hospital) [26];
 Daily allowances (sick leave calculated per day after
the fourth day of absence). The FHI calculates daily
allowances based on patient’s gross wage, and when
sickness leaves are > 31 days, on the number of
dependent children. Conditions vary depending on the
number of hours previously worked (< or > 200 hours
during the previous three months) and the
duration of sickness leave (< or > 6 months).
However, in the present study the number of
dependent children was not considered because
sickness leaves were < 31 days. Also, we made the
assumption that patients worked > 200 hours during
the three previous months (this variable was not
recorded) and obtained a sickness leave period lower
than six months (i.e., flu sick leaves did not extend
six months). Within this framework, the daily
allowance was equal to 50% of the daily wage. When
gross monthly earnings exceeded the maximum paid
by the FHI, patient’s daily allowances were limited to
the indemnity cap [34], which corresponded to 50%
of the French mean daily wage (2830€ per month in
2011) [35].
The costs associated of influenza B per patient (the
sum of reimbursements for each item) are summarizedfor four age groups: younger children (0–4 years), children
(5–14 years), adults (15–64 years), and elderly (65 years
or more).
A cost estimate for the whole French population [35]
was obtained by applying this cost-related information
to the national incidence estimate for influenza B as cal-
culated by GROG [3,4,23] (Table 1).
Statistical analysis
Resource consumption and costs were summarized using
descriptive statistics. Costs were compared between age
groups using the Kruskal–Wallis test. Significant results
were analyzed via multiple comparisons based on the
rank. A significance value of 5% was retained, and one-
way sensitivity analyses were conducted. Moreover, a
variation of 20% was retained for each parameter value
and illustrated graphically using a tornado diagram. The
uncertainties surrounding the mean costs were assessed
through probabilistic analyses using a non-parametric
bootstrap method. A total of 1,000 simulated bootstrap





During the 2010–2011 flu season in France we observed
an outbreak of flu B/Victoria and A(H1N1)pdm09 vi-
ruses. These outbreaks peaked between week 51/2010
and week 08/2011. Overall, 153 sentinels participated in
the study, recruiting patients between week 02/2011 and
week 15/2011. A total of 460 swabs were confirmed as
influenza B positive. Among these positive cases, 201
(44%) patients were successfully recruited: 115 were
symptom free at D7, and 85 of the remaining 86 were
followed at D28.
Furthermore, 56% of the lab-confirmed flu B swabs
were not included (259), mainly due to the fact that the
virology results were not available on time (nine days
after swab) for the GROG coordination to invite physi-
cians to recruit the patients (Figure 1).
Patients characteristics
The mean age of recruits was 17 years (extremes: 0–84).
Seventy percent were children aged <15, 7% were elderly
aged ≥ 65, and 23% were adults of working age, of whom
31 (over half ) were employed with remuneration. Seven
percent of the recruits were vaccinated against seasonal
influenza, and 8% had a co-morbidity risk condition.
Also, the M/F sex ratio was 1.25. Moreover, among the
20 women aged between 15 and 50, 3 were pregnant. A
total of 115 patients (57%) recovered before day 9 (D9).
The recovery rate before D9 was proportional: 63% of
children, 43% of adults, and 13% of elderly (Table 2).
Table 1 Estimation by age group of the incidence of primary care medical consultations for lab confirmed influenza B
(per 100,000 inhabitants) extrapolated for the whole French population (winter 2010–2011)
Estimation of the incidence of
consultations for influenza B
French population Estimation of influenza B patients
in French population
[CI 95%]
Younger children 6.6% 3 884 625 255 834
(0–4 yo) [4.3 – 8.9%] [166 534 – 345 149]
Older children 12.9% 7 733 990 993 998
(5–14 yo) [10.6 – 15.2%] [816 477 – 1 172 086]
Adults 1.5% 40 808 626 612 246
(15–64 yo) [0.8 – 3.8%] [326 061 – 1 550 320]
Elderly 1.5% 10 661 749 157 268
(≥65 yo) [0.8 – 3.8%] [87 853 – 402 374]
All ages 3.2% 63 088 990 2 019 346
[0.9 – 5.5%] [552 660 – 3 453 491]
Source: GROG[3,4,23], INSEE [35]; yo = years old.
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ician, with children requiring these additional consultations
less than adults and the elderly. Patients mostly returned
to their medical office or made telephone consultations.
Very few emergency services (n = 3) and hospitalizations
(n = 2) were observed, and only in children.Figure 1 Flowchart for subjects included from D0 through the
end of the follow-up period.Drugs were taken by > 90% of patients, mainly for symp-
tomatic relief. Overall, antibiotics were prescribed for 19%
of the patients (all ages); but for the elderly 50%. Also, anti-
virals were prescribed in 20% of the cases.
Work leave was reported by 27 of 31 employed patients.
These patients were out of work an average of 6.5 days
(Box 2, Additional file 2).Costs of influenza B
The estimated average cost of influenza B based on
the FHI perspective was found to be 71.8€ (extremes:
16.1€ - 1876.6€) per patient. However, there were varia-
tions according to the distinct age groups (Table 3). In fact,
costs were significantly different between age groups
(p<0.0001). Costs related to antibiotic prescriptions were
higher for those patients aged ≥ 65 years compared with
the other age classes (p = 0.02).
Table 4 presents the mean drug-related costs for pre-
scriptions containing at least one antibiotic. We observed
that these costs were driven by antibiotic use in the entire
population, with one antibiotic prescribed 46% of the
time. However, when each age group was analyzed
separately, antibiotics were also found to be cost drivers
for children 0–4 years (47%) and adults (54%), but not
for the remaining groups.
In the tornado diagram (Figure 2), the vertical lines
represent the mean cost when all parameters are fixed
at their base value of 71.8€. Using this analysis, we
observed that the most sensitive parameter was the
quantity of daily allowances, which was followed by hos-
pitalizations. In fact, increasing the amount of daily
allowances by 20% increased the mean cost from 71.8€ to
76.2€. Using a non-parametric bootstrap method, the
95% confidence interval related to influenza B mean costs
was found to be 43.6€ – 100.0€.
Table 2 Characteristics of patients included in the study
Number of patients per age group and
percentage of the total number
Younger children Older children Adults Elderly All ages
0-4 yo 5-14 yo 15–64 yo ≥65 yo
n % n % n % n % n %
50 25% 91 45% 46 23% 14 7% 201 100%
Age (yo) mean ± SD 2.6 ± 1.3 9.3 ± 2.8 31.5 ± 13.7 72.1 ± 5.7 17.1 ± 19.7
Risk factors 2 4% 5 5% 5 11% 5 36% 17 8%
Pregnancy NA NA 3 NA 3
BMI > 30 0 1 0 0 1
Chronic disease 2 4 2 5 13
Working age (>15 y) - - - - 40 87% 14 100% 54 27%
Employed - - - - 31 78% 0 - 31 57%
Recovering at day 7 ± 2 37 74% 52 57% 20 43% 6 43% 115 57%
NA = non applicable; yo = years old; BMI = body mass index.
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An extrapolation to the national population was based
on an incidence rate of 3.2% of French people (2 million
persons) with influenza B consulting a physician [4]. An
estimation of the costs associated with influenza B per
person (by age group and for all ages) is presented in
Table 5. Notably, we estimated that the overall cost of
influenza B to the FHI in 2010–2011 was 145 million
Euros (95% CI: 88–201 millions €).
Discussion
Our study has estimated that the total impact of influ-
enza B in France during the 2010–2011 winter seasonTable 3 Mean costs per influenza B case per age group und
(in Euros, 2011)
0-4 yo (n = 50) 5-14 yo (n = 9
Mean (SD) Mean (SD)
Direct costs (total) 70.0 (261.6) 50.0 (194.8)
Initial consultation at medical office
(GP or pediatrician)
20.7 (1.7) 17.1 (1.6)
Vaccine 0.3 (1.3) 0.2 (1.1)
Follow-up consultations at medical office (GP) 3.3 (9.0) 3.5 (9.8)
Follow-up at domicile (GP) 0.5 (3.6) 0.5 (4.8)
Emergency services 0.0 (0) 1.2 (6.5)
Hospitalization 36.0 (254.3) 19.8 (188.5)
Drugs (total) 6.5 (10.3) 5.5 (8.8)
Antibiotics 0.8 (2.2) 0.6 (1.8)
Antivirals 0.7 (1.5) 0.8 (1.8)
Other drugs 5.0 (9.2) 4.1 (8.5)
Additional tests 2.8 (11.4) 2.2 (12.4)
Daily allowances 0.0 (0) 0.0 (0)
TOTAL 70.0 (261.6) 50.0 (194.8)
yo = years old; GP = general practitioner.was 145 million Euros based on the FHI perspective.
This finding demonstrates the important economic bur-
den associated with influenza B in France. We observed
that the cost generated by infected children exceeds that
of other age groups when only direct costs are considered.
Indeed, although only two children were hospitalized, hos-
pitalizations were found to have the highest impact on
costs. On the other hand, in adults, costs were mainly
affected by daily allowances due to work leave.
Limitations
Studies based on routine operational data can be ex-
posed to potential biases, which might arise from theer the perspective of the French Health Insurance
1) 15-64 yo (n = 46) ≥65 yo (n = 14) All ages (n = 201) p-value
Mean (SD) Mean (SD) Mean (SD)
33.4 (19.8) 41.8 (18.2) 50.6 (184.7) <0.0003
15.5 (1.0) 15.1 (0) 17.5 (2.4) <0.0001
0.3 (1.3) 3.6 (3.2) 0.5 (1.7) <0.0001
7.0 (11.0) 11.9 (13.5) 4.9 (10.4) 0.0039
1.9 (7.8) 3.2 (11.8) 1.0 (6.1) 0.2718
0.0 (0) 0.0 (0) 0.5 (4.4) 0.3126
0.0 (0) 0.0 (0) 17.9 (179.0) 0.7529
5.9 (5.5) 6.0 (6.2) 5.9 (8.4) 0.7705
0.8 (2.0) 1.8 (2.9) 0.8 (2.0) 0.0214
2.3 (3.5) 1.1 (2.7) 1.1 (2.4) 0.0523
2.8 (3.3) 3.1 (3.9) 4.0 (7.6) 0.7518
2.8 (11.2) 2.1 (5.3) 2.5 (11.4) 0.5985
92.7 (174.2) 0.0 (0) 21.2 (91.4) <0.0001
126.1 (179.6) 41.8 (18.2) 71.8 (205.1) <0.0001
Table 4 Mean drug-related costs for prescriptions
containing at least one antibiotic prescribed per influenza B
case per age group under the perspective of the French
Health Insurance (in Euros, 2011)
0-4 yo 5-14 yo 15-64 yo ≥65 yo All ages
(n = 9) (n = 16) (n = 10) (n = 3) (n = 38)
Mean % € % € % € % € %
Drugs (total) 10.5 9.7 8.1 6.7 9.2
Antibiotics 5.0 47% 4.3 44% 4.4 54% 1.2 19% 4.2 46%
Antivirals 2.5 24% 0.2 2% 1.5 19% 3.8 56% 1.4 15%
Others 3.0 29% 5.2 54% 2.2 27% 1.7 25% 3.6 39%
Silva et al. BMC Public Health 2014, 14:56 Page 6 of 10
http://www.biomedcentral.com/1471-2458/14/56behavior of recruited subjects and/or selection by physi-
cians. Recruitment to the study was initiated with a posi-
tive swab for influenza B. Thus, the extent to which the
swabbing procedure might be selective is critical. Diag-
noses were clinically based, and although guidance was
given, strictly standard definitions are difficult due to the
general symptoms of influenza.
Swab specimens were collected from consenting patients
on an opportunistic basis. Therefore, these samples could
have been influenced by several factors (e.g., the pressures
of work and the time of the day). However, we are not
aware of any bias that might have systematically prejudiced
the incidence of laboratory-confirmed influenza positive
samples. Moreover, GROG reports showed that ad-hoc
and random selection of patients indicated good distribu-
tion based on age group [4].
Furthermore, limitations of the present study included
possible selection bias for more susceptible patients (e.g.,
young infants and pregnant women) and reduced re-
cruitments based on delays in the following processes:Figure 2 Sensitivity of the cost of influenza B in France (tornado diag
variation of the value of each parameter). Legend: The length of the ba
overall cost is sensitive to that particular variable. The graph presented so t
top. The vertical line represents the mean overall cost when all the parame1) transport of samples to the laboratory, 2) virological
lab analysis, 3) transfer of lab results to the GROG, and
4) informing physicians of positive results (subsequently
slowing patient contact).
Also, we have no further information, after the swab
consultation, regarding the evolution of patients not in-
cluded (259) in the study (e.g., if they had complications,
if they were hospitalized). However, information col-
lected (D0 form) on the swabbing day from patients not
included in the study indicates that, in general, their
characteristics were similar to our study population (Box 3,
Additional file 3). Although the distribution of patients
among age groups between the two populations was com-
parable, the proportion of adults was higher in the popula-
tion not included. Moreover, the proportion of elderly was
lower, but not significant. In addition, the proportion of
males in the population not included was lower, with an
insignificant M/F sex ratio of 1.02. There was also a signifi-
cantly higher mean age for children (aged 5–14 years) in-
cluded in the study (p < 0.001). Based on analysis of the
population not included, it appears that no important dif-
ferences in cost calculations or drivers were generated,
except for perhaps the amount of overall costs.
Notably, our study only considered those patients
consulting GROG physicians in general practice and
pediatrics. Thus, patients directly admitted to hospitals
or emergency departments (EDs) were not taken into ac-
count. According to the French Institute for Public
Health Surveillance (InVS), during the influenza season
studied, there were 17 019 ED visits for influenza-like ill-
ness and 919 hospitalizations observed within those ser-
vices participating in the surveillance network. Overall, this
represents 0.03% and 0.001% of the French population,
respectively. Therefore, the weekly average proportion oframs are used to graphically illustrate the impact of ±20%
r for each parameter represents the extent to which the mean of
hat the most influential parameter (the one with the longest bar) is on
ters are at their base value.




Cost per patient (€)
[CI 95%]
French population
flu B + (estimation)
Costs for the FHI* (€)
[CI 95%]
Younger children 50 70.0 255 834 17 908 380
(0–4 yo) [0.4 – 139.6] [102 333 – 35 714 426]
Older children 91 50.0 993 998 49 699 900
(5–14 yo) [12.0 – 88.0] [11 927 976 – 87 471 824]
Adults 46 126.1 612 246 77 204 220
(15–64 yo) [74.9 – 177.3] [45 857 225 – 108 551 215]
Elderly 14 41.8 157 268 6 573 802
(≥65 yo) [32.9 – 50.7] [5 174 117 – 7 973 488]
All ages 201 71.8 2 019 346 144 989 042
[43.6 – 100.0] [88 043 485 – 201 934 600]
*costs include direct costs plus daily allowances for adults (more than 3 days of sick leave) under the perspective of the French Health Insurance (FHI); yo = years old.
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talizations was 0.14% [36]. In the present study, we found
that the proportion of hospitalizations following an ARI
consultation in primary care was 0.3%. Based on this data,
the direct access of patients to EDs and hospitals due to
influenza is not very important when considering care fol-
lowing primary consultation. Therefore, although the ex-
clusion of those expenses represented a possible limitation
of our study, it was not likely have a critical influence on
our final results.
According to the National Council of the College of
Physicians, there were 96 669 active physicians (GPs and
pediatricians) working regularly in France during the
time of this investigation [37]. Members of the GROG
network for the 2010–2011 winter season included 506
volunteer GPs and pediatricians, and 30% of these par-
ticipated in our study. The two referenced laboratories
partners of the GROG network provided 60% of the
virological information [4]. Although our entire study
population was made up of patients with lab-confirmed
influenza B, they came from specific regions of France,
representing 65% of the country (NIC North and South).
Patient characteristics, healthcare consumption
and sick leave
A total of 6.7% of the French population was affected by
influenza during our study period, and two influenza
viruses were dominant: influenza B (3.2%) and influenza
A(H1N1)pdm09 (3.5%). Notably, our investigation corre-
sponded to a post-pandemic influenza season, which may
have influenced the attitudes of patients and physicians
(e.g., higher rate of antiviral prescriptions) [4]. Neverthe-
less, according to the GROG network, the number of
consultations due to ARI was not higher than the usual
rate observed during ordinary annual influenza out-
breaks [4]. However, children were more likely to consultphysicians than adults, which may have biased the aver-
age age of our study population. Consequently this may
have influenced our results regarding higher costs for
children.
Also, the small sample of elderly patients included may
have resulted from a high vaccination coverage (54% in
France 2011), which could have decreased influenza com-
plications and consultations in this age group. In addition,
elderly usually consult later than 48 h following the onset
of symptoms. Indeed, this factor represents an important
exclusion criterion for specimen collection in the GROG
network [38].
Although the rate of employment in our working age
population (67%) was rather high when compared to the
French employment rate (58%), it was not statistically
significant [35]. Notably, a lower employment rate (54%)
was observed during a GROG study conducted during
the 2005–2006 influenza season (also influenza B as
dominant virus) [3], but the difference was also found to
be insignificant when compared to the general French
employment rate. We believe that our sample was repre-
sentative of the general population; however, our costs
may have possibly been overestimated.
From a societal perspective, each case of influenza in
working people leads to between three and seven lost
working days [39]. In Europe, influenza accounts for
approximately 10% of sickness-related absences from
work, while the cost of productivity lost in France and
Germany has been estimated to be in the range of 9.3–
14.1 billion USD per year [39]. Our results are comparable
with these previous findings: adults with remunerated jobs
displayed an average of 6.5 days of sick leave, which repre-
sented 13% of the population absent from work. In
addition, we also calculated the work days lost by parents
as a result of child illness. Although the FHI provides no
daily allowances in these cases, it is important to state that
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out of work for approximately 2.8 days under these cir-
cumstances. In fact, a recent socioeconomic study con-
ducted in Hong Kong with hospitalized children reported
an average of 5.3 ± 3.6 days of school leave for patients
with lab-confirmed influenza B [40]. Indeed, our estimated
school leave for treated children was similar (5.6 days).
The indemnity cap considered for daily allowances
was critical for our obtained results. Since we were not
allowed to collect personal information from the in-
cluded patients, we considered French mean daily wage
in 2011 [35]. Since the indemnity cap may not exceed the
upper limit of daily allowances paid by the FHI, we ap-
plied the latter. We believe that careful considerations
should be taken into account when extrapolating our re-
sults, due to possible over or underestimation of these
cost calculations.
Cost of influenza B
The cost drivers for each age group varied. Our findings
revealed that hospitalization was the major driver (51%)
in younger children, whereas for older children costs
were driven by hospitalization (40%) and initial consult-
ation (34%). Daily allowances represented 73% of costs
in adults. In contrast, for the elderly, the main driver
was medical consultations (72%). Some authors have
found similar drivers; however, others have also identi-
fied costs associated with vaccine administration, which
was not assessed in our study [41,42].
Levy reported the only similar economic analysis of
the burden of influenza illness in France for the seasons
between 1985 and 1989. In the study by Levy, costs were
estimated exclusively based on clinical incidence data re-
lated to influenza-like illness from the perspectives of
both FHI and society [19]. Indeed, the results of our
study are comparable with those presented by Levy.
Both studies highlight to the economic importance of
sick leave: first three days paid by the employer, followed
by the FHI after the fourth day. According to Levy, FHI
carried 70% of costs associated with influenza and the
remaining 30% referred to the societal perspective (FHI
excluded). This suggests that if we had measured the so-
cietal perspective in our study, the costs of influenza B
might have increased by 43%. Thus, a further analysis of
all indirect costs, including lost productive capacity and
costs associated with the employment of substitute
workers, will be needed in future studies. Additionally,
different perspectives (e.g., patient, employer, private and
mutual funds) could be considered.
Furthermore, Carrat et al. published an influenza bur-
den of illness study that intended to obtain data for im-
proving the cost-effectiveness of strategies against the
disease, but no cost analyses were performed. Neverthe-
less, in the same study, the authors found that the meannumber of sick leave for working adults was 4.0 ±
2.8 days [20]. In comparison, in our study, we found a
higher duration (6.5 days) of sick leave among working
age patients.
According to the French Ministry of Health, during
the 2010–2011 influenza season, nearly 10 million
people were targeted by the national influenza vaccin-
ation program, receiving an invitation from the French
Health Insurance to obtain free vaccination. Among
them, 51.8% were vaccinated [43]. Considering this vac-
cination coverage (approximately 5 million people), we
estimate that the expenses related to vaccine cost and
administration for the FHI would be around 110 mil-
lion Euros. This amount is likely to be underestimated,
as we did not consider expenses related to the national
influenza program, institutional campaigns, postal ser-
vices, and other indirect costs. Indeed, there is no pub-
lic information available related to theses expenses.
However, according to the estimates described above,
we suggest that investments on vaccination strategies
are still less expensive than the costs avoided with in-
fluenza care.
Conclusions
To our knowledge, this is the first cost study specifically
related to influenza B in France. Our findings highlight
avoidable costs related to influenza and are valuable in
the context of evaluating healthcare interventions and
public health strategies using economic models.
There is a lack of published literature about the costs
associated with different viral strains of influenza. Thus,
further knowledge is crucially required for policy makers
to effectively decide on strategies regarding influenza (e.g.,
market access and reimbursement for new vaccines, imple-
mentation of vaccination programs in a pandemic situ-
ation). Therefore, we propose that refined studies targeting
influenza economics should be developed in order to facili-
tate the work of policy-makers.
Furthermore, our results have the potential to influence
decisions concerning seasonal influenza vaccine formula-
tion. Currently, the most common available seasonal in-
fluenza vaccine contains only one lineage of influenza B
(together with two flu A strains) [22]. Immunization
against B virus strains of one lineage provides limited
cross-protection against strains of the other lineage
[18]. For this reason, and the difficulty of predicting which
B virus lineage will predominate during a given season,
vaccines containing two influenza B strains (together
with two flu A strains) are recently receiving marketing
authorization [15,18]. Therefore, policy-makers are evalu-
ating the benefit of adopting those vaccines into their
national influenza programs. Further investigations into
the impact of such quadrivalent vaccines and vaccine
effectiveness will be required.
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